Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Strikes Deal to Develop CDx for Incyte's Cancer Drugs

NEW YORK (GenomeWeb News) – Roche's Ventana Medical Systems today announced a collaboration to develop companion diagnostics for Incyte's oncology drug programs.

The first test will be developed for Incyte's ID01 inhibitor program, Ventana said, adding it will support Incyte's efforts using its expertise in companion diagnostics, immunohistochemistry technology platforms, and customer support.

Financial and other terms of the deal were not disclosed.

"With the advancement of INCB24360 into multiple Phase II studies, our first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics," Victor Sandor, Incyte's group vice president, clinical development, said in a statement.

The agreement follows a deal between Ventana and Boehringer Ingelheim to develop companion diagnostics for cancer drugs in the German drug firm's pipeline. In September, Chinese regulators approved Ventana's ALK immunohistochemistry assay as a companion diagnostic for Pfizer's Xalkori (crizotinib) therapy.